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tree should be already cut down, but it is so rooted in the ground 
that it is no longer possible.  
A famous Ukrainian poet Shevchenko said: «Well, it 
seems the words, words and voice nothing more, but the heart 
beats and revives when it hears them». And a medical student 
revives when he or she hears a familiar Latin word or phrase, 
because sometimes it is easier for a student to hear a term in Latin 
than several times in Ukrainian or English. The first thing we 
encounter at the medical institute is knowledge of Latin. We start 
using it from the first lesson in Human Anatomy, Histology, 
Medical Biology and other subjects. Latin is incredibly beautiful 
and quite melodic, but in its turn rather complicated. 
Latin is the most important language in medicine. By the 
way, all medicines and diagnoses were derived from Latin or 
Greek. By learning to recognize different components you can 
understand the meanings of the new words in clinical 
terminology. For prescribing medicaments a future physician 
should master a special structure of a Latin prescription because 
the international pharmacological nomenclature has generally 
been based on the Latin language. That’s why all prescriptions are 
written in Latin and any spelling mistake can cost a person`s life. 
That is why every medical student requires a good knowledge of 
Latin. 
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The review is devoted to the current biomedical direction in 
cell-replacement therapy - therapeutic cloning, which is the most 
universal approach for obtaining patient-specific embryonic stem 
cell lines (hESC) with tremendous potential in maintaining and 
restoring human health.  
Now the main sources of stem cells directly for biomedical 
work are stem cells from umbilical cord blood and adult stem 
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cells. Both sources have serious limitations: umbilical cord blood 
stem cells are autogenous only to the newly born, and receiving 
stem cells from the patient himself is unsafe for him. In addition, 
in general opinion, the potential for differentiation in these cells is 
lower than in ESCs. Obviously, the most versatile and reliable 
source of human stem cell (SC) production is through cloning 
technology. 
To date, fundamental scientific and technological aspects do 
not create barriers to therapeutic cloning. And although there are 
already about 500 human ESC lines in the world, none of them 
have been obtained by cloning technology — by nuclear 
transplantation. Two sensational publications in the journal 
Science for 2004 and 2005 of South Korean scientists on 
receiving individual ESC lines for 11 seriously ill patients turned 
out to be unreliable. There is a report about obtaining a patient-
specific line from activated parthenogenetic human oocytes 
containing histocompatible stem cells for an oocyte donor, a 
potential patient in whose treatment it is already possible to use 
autogenic cells without an immune rejection reaction. Another 
achievement is the production of cloned human embryos with 
fibroblast nuclei that developed to the blastocyst stage, but the 
ESC lines were not created. 
At the same time, an intensive search is underway in the 
world for alternative possibilities for obtaining patient-specific 
ESC lines for biomedical purposes. The most promising 
alternative approach for creating patient-specific lines from 
somatic cells for biomedical purposes is to obtain KSK-like cells 
or induced pluripotent SC CiPSD lines. This is a new area of 
research in cell replacement therapy, initiated by the work of 
Japanese scientists in 2006 on mice to reprogram fibroblasts to a 
status similar to pluripotent. The possibility of such a 
transformation for human fibroblasts was soon shown. Genetic 
modification of fibroblasts was performed by retroviral 
transfection of four key pluripotency factors: 0ct3 / 4, Sox2, Klf4, 
c-Myc, and subsequent expression of these genes induced 
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reprogramming of somatic cells with a return to pluripotent state. 
Although the effectiveness of this approach was very low, and it is 
also known that the use of viral vectors can lead to malignancy of 
iPS cells, these works became a sensation. A whole series of 
studies with induction factors followed, and an active search was 
undertaken for other ways of introducing genes into somatic cells 
(without resorting to retroviruses) with minimizing the 
modification of the genome. As a result, the possibility of a safe 
method of reprogramming cells using transposons and only one 
Klf4 factor was shown in mice. 
However, it is too early to consider iPS cells to be an 
adequate alternative replacement for ESCs for regenerative 
therapy. For biomedical purposes, it is necessary to reprogram 
your own cell genes instead of adding new copies, and only 
therapeutic cloning technologies provide a unique opportunity for 
such reprogramming of somatic cell nuclei. The reversibility of 
the gene expression program under the influence of the oocyte 
cytoplasm, a return to the pattern of embryonic expression in 
somatic donor nuclei allows us to consider reconstructed human 
embryos as the main source for obtaining patient-specific ESC 
lines. 
The unique value of ESCs for medicinal purposes 
determines a serious need for the development of therapeutic 
cloning in our country. It is possible to accomplish the tasks of 
therapeutic cloning on the basis of reproduction centers, which, in 
addition to their direct purpose, can become centers for obtaining 
ESC lines, primarily for women patients of this center and any 
members of their families. It can be expected that with the 
development of therapeutic technologies, obtaining one's own 
ESCs will become available to everyone. It is necessary to carry 
out close cooperation of reproduction centers with relevant 
research laboratories focused on solving fundamental problems 
and developing new technologies. 
 
